Dear Stakeholders, As we step into 2025, I’d like to take a moment to reflect on the remarkable progress we’ve made in the CRISPR landscape over the past year and look ahead to the opportunities before us. The achievements of 2024 have underscored CRISPR’s growing significance across industries and have reinforced ERS Genomics’ central role in expanding access to this transformative technology. A Year of Milestones The momentum behind CRISPR reached a new high in December 2023 with the FDA’s landmark approval of the world’s first CRISPR therapy, Casgevy (exagamglogene autotemcel). Offering a potentially curative “one-and-done” treatment for sickle cell